CorMedix reported quarterly EPS of $0.43, beating the Zacks consensus estimate of $0.35 by $0.08, or about 23%. Results also improved from $0.30 per share a year ago, indicating year-over-year earnings growth. The update is positive for the stock but is limited to a routine earnings beat without guidance or other new catalysts.
CorMedix reported quarterly EPS of $0.43, beating the Zacks consensus estimate of $0.35 by $0.08, or about 23%. Results also improved from $0.30 per share a year ago, indicating year-over-year earnings growth. The update is positive for the stock but is limited to a routine earnings beat without guidance or other new catalysts.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
